Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 19'th Mar 2026
CONSHOHOCKEN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc
2,600 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Bamco Inc. NY
03:36am, Tuesday, 17'th Mar 2026
Bamco Inc. NY bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by ArrowMark Colorado Holdings LLC
05:34am, Sunday, 15'th Mar 2026
ArrowMark Colorado Holdings LLC lowered its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) by 14.9% during the third quarter, according to its most recent disclosure with the Secu
32,662 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Ally Bridge Group NY LLC
04:02am, Sunday, 15'th Mar 2026
Ally Bridge Group NY LLC bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) during the third quarter, according to the company in its most recent filing with the Securities and Exchan
120,000 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Purchased by Alkeon Capital Management LLC
03:28am, Sunday, 15'th Mar 2026
Alkeon Capital Management LLC bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) during the third quarter, according to the company in its most recent filing with the Securities and E
Barclays PLC Cuts Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
03:59am, Thursday, 12'th Mar 2026
Barclays PLC lowered its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) by 20.4% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 49,912
2 Under-the-Radar Stocks to Buy and Hold
01:13pm, Tuesday, 10'th Mar 2026
Axsome Therapeutics has an exciting late-stage pipeline. Madrigal Pharmaceuticals is looking to dominate a large market with significant unmet needs.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 05'th Mar 2026
CONSHOHOCKEN, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc
Corcept Therapeutics (NASDAQ:CORT) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) Head to Head Contrast
04:34am, Tuesday, 03'rd Mar 2026
Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Report) and Corcept Therapeutics (NASDAQ: CORT - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will compare
Artisan Partners Limited Partnership Acquires 4,683 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
04:24am, Saturday, 28'th Feb 2026
Artisan Partners Limited Partnership grew its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) by 2.3% in the undefined quarter, according to the company in its most recent 13F filing with th
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
08:00am, Tuesday, 24'th Feb 2026
CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down
11:01am, Friday, 20'th Feb 2026
MDGL swings to a wider Q4 loss as expenses surge, but Rezdiffra sales top estimates and fuel revenue growth. The stock slides 11% in response to the mixed nature of the results.
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down After Earnings Miss
03:39am, Friday, 20'th Feb 2026
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL - Get Free Report)'s stock price gapped down before the market opened on Thursday following a weaker than expected earnings announcement. The stock had pre
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
11:45am, Thursday, 19'th Feb 2026
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates
09:16am, Thursday, 19'th Feb 2026
Madrigal (MDGL) came out with a quarterly loss of $2.57 per share versus the Zacks Consensus Estimate of $0.04. This compares to a loss of $2.71 per share a year ago.
